Impact of the COVID-19 related border restrictions on influenza and other common respiratory viral infections in New Zealand.
acute respiratory illness
common respiratory viral infections
influenza infection
public health and social measures
respiratory syncytial viral infection
severe acute respiratory infections
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
12
12
2023
received:
29
10
2023
accepted:
13
12
2023
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
13
2
2024
Statut:
ppublish
Résumé
New Zealand's (NZ) complete absence of community transmission of influenza and respiratory syncytial virus (RSV) after May 2020, likely due to COVID-19 elimination measures, provided a rare opportunity to assess the impact of border restrictions on common respiratory viral infections over the ensuing 2 years. We collected the data from multiple surveillance systems, including hospital-based severe acute respiratory infection surveillance, SHIVERS-II, -III and -IV community cohorts for acute respiratory infection (ARI) surveillance, HealthStat sentinel general practice (GP) based influenza-like illness surveillance and SHIVERS-V sentinel GP-based ARI surveillance, SHIVERS-V traveller ARI surveillance and laboratory-based surveillance. We described the data on influenza, RSV and other respiratory viral infections in NZ before, during and after various stages of the COVID related border restrictions. We observed that border closure to most people, and mandatory government-managed isolation and quarantine on arrival for those allowed to enter, appeared to be effective in keeping influenza and RSV infections out of the NZ community. Border restrictions did not affect community transmission of other respiratory viruses such as rhinovirus and parainfluenza virus type-1. Partial border relaxations through quarantine-free travel with Australia and other countries were quickly followed by importation of RSV in 2021 and influenza in 2022. Our findings inform future pandemic preparedness and strategies to model and manage the impact of influenza and other respiratory viral threats.
Sections du résumé
BACKGROUND
BACKGROUND
New Zealand's (NZ) complete absence of community transmission of influenza and respiratory syncytial virus (RSV) after May 2020, likely due to COVID-19 elimination measures, provided a rare opportunity to assess the impact of border restrictions on common respiratory viral infections over the ensuing 2 years.
METHODS
METHODS
We collected the data from multiple surveillance systems, including hospital-based severe acute respiratory infection surveillance, SHIVERS-II, -III and -IV community cohorts for acute respiratory infection (ARI) surveillance, HealthStat sentinel general practice (GP) based influenza-like illness surveillance and SHIVERS-V sentinel GP-based ARI surveillance, SHIVERS-V traveller ARI surveillance and laboratory-based surveillance. We described the data on influenza, RSV and other respiratory viral infections in NZ before, during and after various stages of the COVID related border restrictions.
RESULTS
RESULTS
We observed that border closure to most people, and mandatory government-managed isolation and quarantine on arrival for those allowed to enter, appeared to be effective in keeping influenza and RSV infections out of the NZ community. Border restrictions did not affect community transmission of other respiratory viruses such as rhinovirus and parainfluenza virus type-1. Partial border relaxations through quarantine-free travel with Australia and other countries were quickly followed by importation of RSV in 2021 and influenza in 2022.
CONCLUSION
CONCLUSIONS
Our findings inform future pandemic preparedness and strategies to model and manage the impact of influenza and other respiratory viral threats.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13247Subventions
Organisme : NIAID NIH HHS
ID : 75N93021C00016
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Informations de copyright
© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
New_Zealand_Government. New Zealand COVID-19 alert levels summary. https://covid19.govt.nz/assets/resources/tables/COVID-19-alert-levels-summary.pdf. 2020; (4-Sept-2020).
Jefferies S, French N, Gilkison C, et al. COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. Lancet Public Health. 2020;5(11):e612-e623. doi:10.1016/S2468-2667(20)30225-5
Binny RN, Baker MG, Hendy SC, et al. Early intervention is the key to success in COVID-19 control. R Soc Open Sci. 2021;8(11):210488. doi:10.1098/rsos.210488
Baker MG, Wilson N, Anglemyer A. Successful elimination of Covid-19 transmission in New Zealand. N Engl J Med. 2020;383(8):e56. doi:10.1056/NEJMc2025203
Huang QS, Wood T, Jelley L, et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nature Communications. 2021;12(1):1001. doi:10.1038/s41467-021-21157-9
Organization WH. Updated WHO recommendations for international traffic in relation to COVID-19 outbreak. 2020.
Shiraef MA, Friesen P, Feddern L, Weiss MA, Team C. Did border closures slow SARS-CoV-2? Sci Rep-Uk. 2022;12(1):1709. doi:10.1038/s41598-022-05482-7
New_Zealand_Government. New Zealand border to reopen in stages. 2022. from 27 February 2022. https://covid19.govt.nz/news-and-data/latest-news/new-zealand-border-to-reopen-in-stages-from-27-february/
Lei H, Wu X, Wang X, et al. Different transmission dynamics of coronavirus disease 2019 (COVID-19) and influenza suggest the relative efficiency of isolation/quarantine and social distancing against COVID-19 in China. Clin Infect Dis. 2021;73(11):e4305-e4311. doi:10.1093/cid/ciaa1584
Lei H, Xu M, Wang X, et al. Nonpharmaceutical interventions used to control COVID-19 reduced seasonal influenza transmission in China. J Infect Dis. 2020;222(11):1780-1783. doi:10.1093/infdis/jiaa570
Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet Public Health. 2020;5(5):e279-e288. doi:10.1016/S2468-2667(20)30090-6
Hsieh CC, Lin CH, Wang WYC, Pauleen DJ, Chen JV. The outcome and implications of public precautionary measures in Taiwan-declining respiratory disease cases in the COVID-19 pandemic. Int J Environ Res Public Health. 2020;17(13):4877. doi:10.3390/ijerph17134877
Soo RJJ, Chiew CJ, Ma S, Pung R, Lee V. Decreased influenza incidence under COVID-19 control measures, Singapore. Emerg Infect Dis. 2020;26(8):1933-1935. doi:10.3201/eid2608.201229
Bhatt P, Strachan J, Easton M, Franklin L, Drewett G. Effect of COVID-19 restrictions and border closures on vaccine preventable diseases in Victoria, Australia, 2020-2021. Commun Dis Intell. 2018;2022:46. doi:10.33321/cdi.2022.46.29
Qiu Z, Cao Z, Zou M, et al. The effectiveness of governmental nonpharmaceutical interventions against COVID-19 at controlling seasonal influenza transmission: an ecological study. BMC Infect Dis. 2022;22(1):331. doi:10.1186/s12879-022-07317-2
Huang QS, Turner N, Baker MG, et al. Southern hemisphere influenza and vaccine effectiveness research and surveillance. Influenza Other Respi Viruses. 2015;9(4):179-190. doi:10.1111/irv.12315
Huang QS, Baker M, McArthur C, et al. Implementing hospital-based surveillance for severe acute respiratory infections caused by influenza and other respiratory pathogens in New Zealand. Western Pac Surveill Response J. 2014;5(2):23-30. doi:10.5365/wpsar.2014.5.1.004
Lopez L, Wood T, Prasad N, Huang QS. Influenza surveillance in New Zealand, 2015. 2016. https://surv.esr.cri.nz/PDF_surveillance/Virology/FluAnnRpt/InfluenzaAnn2015.pdf
ESR. Flu surveillance and research 2022. https://www.esr.cri.nz/our-services/consultancy/flu-surveillance-and-research
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
Vega T, Lozano JE, Meerhoff T, et al. Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method. Influenza Other Respi Viruses. 2015;9(5):234-246. doi:10.1111/irv.12330
Vega T, Lozano JE, Meerhoff T, et al. Influenza surveillance in Europe: establishing epidemic thresholds by the moving epidemic method. Influenza Other Respi Viruses. 2013;7(4):546-558. doi:10.1111/j.1750-2659.2012.00422.x
Eden JS, Sikazwe C, Xie R, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun. 2022;13(1):2884. doi:10.1038/s41467-022-30485-3
O'Neill GK, Janette TJ, Jen Kok J, et al. Circulation of influenza and other respiratory viruses during the COVID-19 pandemic in Australia and New Zealand, 2020-2021. Western Pacific Surveillance and Response Journal. 2022. Accepted in press.
Huang QS, Lopez LD, McCallum L, Adlam B. Influenza surveillance and immunisation in New Zealand, 1997-2006. Influenza Other Respi Viruses. 2008;2(4):139-145. doi:10.1111/j.1750-2659.2008.00050.x
WHO. Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza 2019; (20190101).. https://appswhoint/iris/bitstream/handle/10665/329438/9789241516839-engpdf
World_Health_Organization_Writing_Group, Bell D, Nicoll A, et al. Non-pharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis. 2006;12(1):81-87. doi:10.3201/eid1201.051370
Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature. 2006;442(7101):448-452. doi:10.1038/nature04795
Scalia Tomba G, Wallinga J. A simple explanation for the low impact of border control as a countermeasure to the spread of an infectious disease. Math Biosci. 2008;214(1-2):70-72. doi:10.1016/j.mbs.2008.02.009
Yeoh DK, Foley DA, Minney-Smith CA, et al. Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin Infect Dis. 2021;72(12):2199-2202. doi:10.1093/cid/ciaa1475
Tang JW, Bialasiewicz S, Dwyer DE, et al. Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. J Med Virol. 2021;93(7):4099-4101. doi:10.1002/jmv.26964
Sullivan SG, Carlson S, Cheng AC, et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, march to September 2020. Euro Surveill. 2020;25(47). doi:10.2807/1560-7917.ES.2020.25.47.2001847
Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased influenza activity during the COVID-19 pandemic - United States, Australia, Chile, and South Africa, 2020. Mmwr. 2020;69(37):1305-1309. doi:10.15585/mmwr.mm6937a6
Tempia S, Walaza S, Bhiman JN, et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Euro Surveill. 2021;26(29). doi:10.2807/1560-7917.ES.2021.26.29.2001600
Foley DA, Yeoh DK, Minney-Smith CA, et al. The Interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis. 2021;73(9):e2829-e2830. doi:10.1093/cid/ciaa1906
van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Euro Surveill. 2021;26(29). doi:10.2807/1560-7917.ES.2021.26.29.2100639
Britton PN, Hu N, Saravanos G, et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health. 2020;4(11):e42-e43. doi:10.1016/S2352-4642(20)30307-2
Winther B, McCue K, Ashe K, Rubino JR, Hendley JO. Environmental contamination with rhinovirus and transfer to fingers of healthy individuals by daily life activity. J Med Virol. 2007;79(10):1606-1610. doi:10.1002/jmv.20956
Peltola V, Waris M, Osterback R, Susi P, Ruuskanen O, Hyypia T. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections. J Infect Dis. 2008;197(3):382-389. doi:10.1086/525542
Muchmore HG, Parkinson AJ, Humphries JE, et al. Persistent parainfluenza virus shedding during isolation at the south pole. Nature. 1981;289(5794):187-189. doi:10.1038/289187a0
Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144(5):433-441. doi:10.1093/infdis/144.5.433
Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110(5):1681-1688. doi:10.1182/blood-2006-12-060343
Baker MG, Durrheim D, Hsu LY, Wilson N. COVID-19 and other pandemics require a coherent response strategy. Lancet. 2023;401(10373):265-266. doi:10.1016/S0140-6736(22)02489-8